Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Marvell Technology Inc (MRVL) Price & Performance

GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.

The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.

Marvell Technology (MRVL) trades at $245.28, down 7.74% over 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $327.86 implying significant upside. The company reported three consecutive quarterly EPS beats, with Q3 2026 expected at $1.1, and projects robust revenue growth, particularly in its custom AI chip business, which is forecast to more than double by fiscal 2028. Despite a net loss in 2025, improving operating cash flow and a strong gross margin of 52.21% highlight underlying operational strength.

The outlook for MRVL is positive, driven by AI-driven demand in data centers and custom silicon deals with hyperscalers like Google, though high valuation multiples (P/E of 88.98) and execution risks in scaling custom chip production pose challenges. Investor sentiment remains bullish, with 83.79% of analysts rating the stock a buy, but volatility near all-time highs and competitive pressures warrant caution.